Immunocore (NASDAQ:IMCR) Posts Earnings Results, Misses Estimates By $0.15 EPS

Immunocore (NASDAQ:IMCR) released its earnings results on Friday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.15), FiscalAI reports. Immunocore had a negative return on equity of 4.54% and a negative net margin of 4.20%.

Immunocore Price Performance

IMCR stock traded up $2.59 during trading hours on Friday, hitting $30.99. 1,526,513 shares of the stock traded hands, compared to its average volume of 507,836. The company has a current ratio of 4.47, a quick ratio of 4.44 and a debt-to-equity ratio of 0.94. The stock has a 50-day simple moving average of $31.64 and a 200 day simple moving average of $31.73. Immunocore has a one year low of $27.50 and a one year high of $40.71. The company has a market cap of $1.60 billion, a P/E ratio of -83.75 and a beta of 0.82.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on IMCR shares. Mizuho raised their price target on Immunocore from $34.00 to $35.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. TD Cowen raised shares of Immunocore to a “strong-buy” rating in a research note on Monday, August 24th. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Immunocore in a report on Monday, October 26th. Wall Street Zen downgraded Immunocore from a “buy” rating to a “hold” rating in a report on Tuesday, July 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Thursday, October 15th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Immunocore has a consensus rating of “Moderate Buy” and an average target price of $55.86.

Immunocore Company Profile

Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.

The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.